MK-1942

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for MK-1942, covering 2024-08-15 to 2024-10-15. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) [Phase 2]

See pricing